

Specialty Guideline Management

Procysbi

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Procysbi	cysteamine bitartrate delayed-release

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indications¹

Procysbi is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.

All other indications are considered experimental/investigational and not medically necessary.

Documentation

Submission of the following information is necessary to initiate the prior authorization review:

- Initial requests: assay detecting increased cystine concentration in leukocytes or genetic testing results supporting diagnosis.
- Continuation requests: lab results or chart notes documenting a positive response to therapy (e.g., improvement, stabilization, or slowing of disease progression for serum creatinine, calculated creatinine clearance, leukocyte cystine concentration, or maintained growth [height]).

Prescriber Specialties

This medication must be prescribed by or in consultation with a physician who specializes in the treatment of metabolic disease and/or lysosomal storage disorders.

Coverage Criteria

Nephropathic cystinosis^{1,2}

Authorization of 12 months may be granted for treatment of nephropathic cystinosis when all of the following criteria are met:

- Diagnosis of cystinosis was confirmed by the presence of increased cystine concentration in leukocytes or by genetic testing; and
- Member is 1 year of age or older; and
- Member will not use Procysbi in combination with Cystagon.

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the Coverage Criteria section who are responding to therapy (e.g., improvement, stabilization, or slowing of disease progression for serum creatinine, calculated creatinine clearance, leukocyte cystine concentration, or maintained growth [height]).

References

1. Procysbi [package insert]. Deerfield, IL: Horizon Therapeutics USA, Inc.; February 2022.
2. Ivanova E, De Leo MG, De Matteis MA, Levtchenko E. Cystinosis: clinical presentation, pathogenesis, and treatment. *Pediatr Endocrinol Rev.* 2014;12(1):176-184.